These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 19645647

  • 1. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation.
    Degenhardt L, Larance BK, Bell JR, Winstock AR, Lintzeris N, Ali RL, Scheuer N, Mattick RP.
    Med J Aust; 2009 Aug 03; 191(3):161-5. PubMed ID: 19645647
    [Abstract] [Full Text] [Related]

  • 2. The diversion and injection of a buprenorphine-naloxone soluble film formulation.
    Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, White N, Degenhardt L.
    Drug Alcohol Depend; 2014 Mar 01; 136():21-7. PubMed ID: 24461476
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START).
    Potter JS, Marino EN, Hillhouse MP, Nielsen S, Wiest K, Canamar CP, Martin JA, Ang A, Baker R, Saxon AJ, Ling W.
    J Stud Alcohol Drugs; 2013 Jul 01; 74(4):605-13. PubMed ID: 23739025
    [Abstract] [Full Text] [Related]

  • 5. Parenteral buprenorphine-naloxone abuse is a major cause of fatal buprenorphine-related poisoning.
    Häkkinen M, Heikman P, Ojanperä I.
    Forensic Sci Int; 2013 Oct 10; 232(1-3):11-5. PubMed ID: 24053859
    [Abstract] [Full Text] [Related]

  • 6. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.
    Larance B, Dietze P, Ali R, Lintzeris N, White N, Jenkinson R, Degenhardt L.
    Drug Alcohol Rev; 2015 Nov 10; 34(6):603-10. PubMed ID: 25950232
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR, Lea T, Sheridan J.
    Int J Drug Policy; 2008 Dec 10; 19(6):450-8. PubMed ID: 18359216
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L, Iversen J, Wand H, Maher L.
    Addiction; 2021 Mar 10; 116(3):525-535. PubMed ID: 32557931
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F, Biondi L, Calabria R, Fiore A, Peluso E, Vonella D, Rota AG.
    Clin Drug Investig; 2010 Mar 10; 30 Suppl 1():21-6. PubMed ID: 20450242
    [Abstract] [Full Text] [Related]

  • 14. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.
    Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL.
    Am J Drug Alcohol Abuse; 2009 Mar 10; 35(2):68-72. PubMed ID: 19212931
    [Abstract] [Full Text] [Related]

  • 15. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.
    Orman JS, Keating GM.
    Drugs; 2009 Mar 10; 69(5):577-607. PubMed ID: 19368419
    [Abstract] [Full Text] [Related]

  • 16. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C, Favero VD, Zecchinato G, Buson R, Cusin D, Pellachin P, Simonetto P.
    Clin Drug Investig; 2010 Mar 10; 30 Suppl 1():27-31. PubMed ID: 20450243
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec 10; 16(92):232-5. PubMed ID: 18087797
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.